{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T13:52:50Z","timestamp":1790949170816,"version":"4.1.0"},"reference-count":73,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T00:00:00Z","timestamp":1755734400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2023YFC2411603"],"award-info":[{"award-number":["2023YFC2411603"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["World Neurosurgery"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.wneu.2025.124414","type":"journal-article","created":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T16:24:21Z","timestamp":1756398261000},"page":"124414","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Targeted Therapy for Recurrent and Refractory Papillary Craniopharyngioma: A Systematic Narrative Review"],"prefix":"10.1016","volume":"202","author":[{"given":"Yi","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3743-4852","authenticated-orcid":false,"given":"Bo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhao","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhixiong","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.wneu.2025.124414_bib1","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/S0002-9610(32)90942-8","article-title":"Intracranial tumours, notes upon a series of two thousand verified cases with surgical-mortality percentages pertaining thereto","volume":"16","author":"Cushing","year":"1932","journal-title":"Am J Surg"},{"key":"10.1016\/j.wneu.2025.124414_bib2","doi-asserted-by":"crossref","first-page":"547","DOI":"10.3171\/jns.1998.89.4.0547","article-title":"The descriptive epidemiology of craniopharyngioma","volume":"89","author":"Bunin","year":"1998","journal-title":"JNS"},{"key":"10.1016\/j.wneu.2025.124414_bib3","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1097\/00006123-200002000-00007","article-title":"Long-term outcomes for surgically resected craniopharyngiomas","volume":"46","author":"Duff","year":"2000","journal-title":"Neurosurg"},{"key":"10.1016\/j.wneu.2025.124414_bib4","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1093\/neuonc\/nov044","article-title":"Survival, hypothalamic obesity, and neuropsychological\/psychosocial status after childhood-onset craniopharyngioma: newly reported long-term outcomes","volume":"17","author":"Sterkenburg","year":"2015","journal-title":"NEUONC"},{"key":"10.1016\/j.wneu.2025.124414_bib5","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1530\/eje.1.02114","article-title":"Quality of life in treated adult craniopharyngioma patients","volume":"154","author":"Dekkers","year":"2006","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.wneu.2025.124414_bib6","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","article-title":"The 2016 World Health Organization classification of tumors of the central nervous system: a summary","volume":"131","author":"Louis","year":"2016","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.wneu.2025.124414_bib7","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/BF00342596","article-title":"Principles of the new World Health Organization (WHO) classification of brain tumors","volume":"19","author":"Z\u00fclch","year":"1980","journal-title":"Neuroradiology"},{"key":"10.1016\/j.wneu.2025.124414_bib8","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/j.1750-3639.1993.tb00752.x","article-title":"The new WHO classification of brain tumours","volume":"3","author":"Kleihues","year":"1993","journal-title":"Brain Pathol"},{"key":"10.1016\/j.wneu.2025.124414_bib9","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s00401-007-0243-4","article-title":"The 2007 WHO classification of tumours of the central nervous system","volume":"114","author":"Louis","year":"2007","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.wneu.2025.124414_bib10","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1093\/jnen\/61.3.228","article-title":"Commentary on the WHO classification of tumors of the nervous system","volume":"61","author":"Rorke","year":"2002","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.1016\/j.wneu.2025.124414_bib11","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO classification of tumors of the central nervous system: a summary","volume":"23","author":"Louis","year":"2021","journal-title":"NEUONC"},{"key":"10.1016\/j.wneu.2025.124414_bib12","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.wneu.2020.05.172","article-title":"Craniopharyngiomas: challenges and controversies","volume":"142","author":"Asha","year":"2020","journal-title":"World Neurosurg"},{"key":"10.1016\/j.wneu.2025.124414_bib13","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1210\/endrev\/bnac035","article-title":"Contemporary biological insights and clinical management of craniopharyngioma","volume":"44","author":"Apps","year":"2022","journal-title":"Endocr Rev"},{"key":"10.1016\/j.wneu.2025.124414_bib14","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s40478-016-0287-6","article-title":"Adamantinomatous and papillary craniopharyngiomas are characterized by distinct epigenomic as well as mutational and transcriptomic profiles","volume":"4","author":"H\u00f6lsken","year":"2016","journal-title":"Acta Neuropathol Commun"},{"key":"10.1016\/j.wneu.2025.124414_bib15","first-page":"126","article-title":"Genomic alterations of adamantinomatous and papillary craniopharyngioma","volume":"76","author":"Goschzik","year":"2017","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.1016\/j.wneu.2025.124414_bib16","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1056\/NEJMoa1210093","article-title":"Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations","volume":"367","author":"Flaherty","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.wneu.2025.124414_bib17","doi-asserted-by":"crossref","first-page":"71","DOI":"10.21037\/jxym.2017.10.04","article-title":"Personalized therapy in craniopharyngioma\u2014novel perspectives and limitations","volume":"2","author":"Peng","year":"2017","journal-title":"J Xiangya Med"},{"key":"10.1016\/j.wneu.2025.124414_bib18","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1056\/NEJMc1202124","article-title":"BRAF inhibition in refractory hairy-cell leukemia","volume":"366","author":"Dietrich","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.wneu.2025.124414_bib19","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1200\/JCO.2014.57.1950","article-title":"Reproducible and sustained efficacy of targeted therapy with vemurafenib in patients with BRAFV600E-Mutated Erdheim-Chester disease","volume":"33","author":"Haroche","year":"2015","journal-title":"JCO"},{"key":"10.1016\/j.wneu.2025.124414_bib20","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1038\/nature03890","article-title":"BRAFE600-associated senescence-like cell cycle arrest of human naevi","volume":"436","author":"Michaloglou","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.wneu.2025.124414_bib21","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.wneu.2025.124414_bib22","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/ng.2868","article-title":"Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas","volume":"46","author":"Brastianos","year":"2014","journal-title":"Nat Genet"},{"key":"10.1016\/j.wneu.2025.124414_bib23","first-page":"2141","article-title":"MAPK pathway control of stem cell proliferation and differentiation in the embryonic pituitary provides insights into the pathogenesis of papillary craniopharyngioma","volume":"144","author":"Haston","year":"2017","journal-title":"Development"},{"key":"10.1016\/j.wneu.2025.124414_bib24","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1056\/NEJMe2305288","article-title":"Precision oncology for papillary craniopharyngioma","volume":"389","author":"Blakeley","year":"2023","journal-title":"New Engl J Med"},{"key":"10.1016\/j.wneu.2025.124414_bib25","doi-asserted-by":"crossref","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"151","author":"Moher","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.wneu.2025.124414_bib26","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s11060-025-04969-3","article-title":"Papillary craniopharyngioma management in the era of BRAF and MEK inhibition","volume":"173","author":"Damante","year":"2025","journal-title":"J Neuro Oncol"},{"key":"10.1016\/j.wneu.2025.124414_bib27","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1464362","article-title":"Clinical response to dabrafenib plus trametinib in BRAF V600E mutated papillary craniopharyngiomas: a case report and literature review","volume":"14","author":"Hanona","year":"2024","journal-title":"Front Oncol"},{"key":"10.1016\/j.wneu.2025.124414_bib28","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1007\/s40618-024-02382-7","article-title":"Targeted therapy in BRAF mutated aggressive papillary craniopharyngioma: a case report and overview of the literature","volume":"47","author":"Losa","year":"2024","journal-title":"J Endocrinol Invest"},{"issue":"supplement","key":"10.1016\/j.wneu.2025.124414_bib29","first-page":"251","article-title":"Initial presentation of papillary craniopharyngioma with BRAF mutation treated with adjuvant chemotherapy (867)","volume":"94","author":"Gopal","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.wneu.2025.124414_bib30","doi-asserted-by":"crossref","first-page":"e117","DOI":"10.1016\/j.wneu.2023.08.137","article-title":"Case report: successful use of BRAF\/MEK inhibitors in aggressive BRAF-mutant craniopharyngioma","volume":"180","author":"Wu","year":"2023","journal-title":"World Neurosurg"},{"key":"10.1016\/j.wneu.2025.124414_bib31","article-title":"Dramatic response of BRAF V600E mutant papillary craniopharyngioma to targeted therapy","volume":"108","author":"Brastianos","year":"2015","journal-title":"JNCIJ"},{"key":"10.1016\/j.wneu.2025.124414_bib32","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1007\/s11102-023-01339-y","article-title":"Dabrafenib as a diagnostic and therapeutic strategy for the non-surgical management of papillary craniopharyngioma","volume":"26","author":"Lin","year":"2023","journal-title":"Pituitary"},{"key":"10.1016\/j.wneu.2025.124414_bib33","first-page":"826","article-title":"Case report and literature review of BRAF-V600 inhibitors for treatment of papillary craniopharyngiomas: a potential treatment paradigm shift","volume":"47","author":"Nussbaum","year":"2022","journal-title":"Clin Pharm Therapeu"},{"key":"10.1016\/j.wneu.2025.124414_bib34","article-title":"Medical debulking with BRAF\/MEK inhibitors in aggressive BRAF-mutant craniopharyngioma","volume":"2","author":"Di Stefano","year":"2020","journal-title":"Neurooncol Adv"},{"key":"10.1016\/j.wneu.2025.124414_bib35","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.3171\/2019.8.JNS19643","article-title":"Dual BRAF\/MEK therapy in BRAF V600E-mutated primary brain tumors: a case series showing dramatic clinical and radiographic responses and a reduction in cutaneous toxicity","volume":"133","author":"Bernstein","year":"2020","journal-title":"JNS"},{"key":"10.1016\/j.wneu.2025.124414_bib36","doi-asserted-by":"crossref","first-page":"6038","DOI":"10.18632\/oncotarget.27203","article-title":"Newly diagnosed papillary craniopharyngioma with BRAF V600E mutation treated with single-agent selective BRAF inhibitor dabrafenib: a case report","volume":"10","author":"Rao","year":"2019","journal-title":"Oncotarget"},{"key":"10.1016\/j.wneu.2025.124414_bib37","doi-asserted-by":"crossref","first-page":"95","DOI":"10.2217\/cns-2016-0034","article-title":"BRAF-V600E mutant papillary craniopharyngioma dramatically responds to combination BRAF and MEK inhibitors","volume":"6","author":"Roque","year":"2017","journal-title":"CNS Oncol"},{"key":"10.1016\/j.wneu.2025.124414_bib38","doi-asserted-by":"crossref","DOI":"10.2217\/cns-2023-0018","article-title":"Promising response to vemurafenib and cobimetinib treatment for BRAF V600E mutated craniopharyngioma: a case report and literature review","volume":"13","author":"Yu","year":"2024","journal-title":"CNS Oncol"},{"key":"10.1016\/j.wneu.2025.124414_bib39","article-title":"Concurrent radiation and targeted therapy for papillary craniopharyngioma: a case report","volume":"15","author":"Shah","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.wneu.2025.124414_bib40","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.6004\/jnccn.2020.7624","article-title":"Successful use of BRAF\/MEK inhibitors as a neoadjuvant approach in the definitive treatment of papillary craniopharyngioma","volume":"18","author":"Khaddour","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.wneu.2025.124414_bib41","doi-asserted-by":"crossref","first-page":"2910","DOI":"10.1002\/cncr.32197","article-title":"Targeted treatment of papillary craniopharyngiomas harboring BRAF V600E mutations","volume":"125","author":"Tareq","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.wneu.2025.124414_bib42","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.882381","article-title":"Neoadjuvant B-RAF and MEK inhibitor targeted therapy for adult papillary craniopharyngiomas: a new treatment paradigm","volume":"13","author":"Calvanese","year":"2022","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.wneu.2025.124414_bib43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1210\/jendso\/bvab043","article-title":"Aggressive childhood-onset papillary craniopharyngioma managed with vemurafenib, a BRAF inhibitor","volume":"5","author":"Chik","year":"2021","journal-title":"J Endocr Soc"},{"key":"10.1016\/j.wneu.2025.124414_bib44","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1007\/s11102-015-0663-4","article-title":"Pronounced response of papillary craniopharyngioma to treatment with vemurafenib, a BRAF inhibitor","volume":"19","author":"Aylwin","year":"2015","journal-title":"Pituitary"},{"key":"10.1016\/j.wneu.2025.124414_bib45","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.652005","article-title":"Dramatic therapeutic response to dabrafenib plus trametinib in BRAF V600E mutated papillary craniopharyngiomas: a case report and literature review","volume":"8","author":"Fasano","year":"2022","journal-title":"Front Med"},{"key":"10.1016\/j.wneu.2025.124414_bib46","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.3171\/2017.11.JNS172373","article-title":"Recurrent papillary craniopharyngioma with BRAF V600E mutation treated with dabrafenib: case report","volume":"130","author":"Himes","year":"2019","journal-title":"JNS"},{"key":"10.1016\/j.wneu.2025.124414_bib47","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1007\/s00701-017-3311-0","article-title":"Recurrent papillary craniopharyngioma with BRAFV600E mutation treated with neoadjuvant-targeted therapy","volume":"159","author":"Rostami","year":"2017","journal-title":"Acta Neurochir"},{"key":"10.1016\/j.wneu.2025.124414_bib48","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1056\/NEJMoa2213329","article-title":"BRAF\u2013MEK inhibition in newly diagnosed papillary craniopharyngiomas","volume":"389","author":"Brastianos","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.wneu.2025.124414_bib49","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1093\/ejendo\/lvae091","article-title":"BRAF and MEK inhibitor targeted therapy in papillary craniopharyngiomas: a cohort study","volume":"191","author":"De Alcubierre","year":"2024","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.wneu.2025.124414_bib50","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1159\/000504512","article-title":"The diagnosis and treatment of craniopharyngioma","volume":"110","author":"M\u00fcller","year":"2019","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.wneu.2025.124414_bib51","doi-asserted-by":"crossref","first-page":"R139","DOI":"10.1530\/EJE-15-0957","article-title":"Endocrine tumors: BRAF V600E mutations in papillary craniopharyngioma","volume":"174","author":"Brastianos","year":"2016","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.wneu.2025.124414_bib52","doi-asserted-by":"crossref","first-page":"e148","DOI":"10.1016\/j.wneu.2022.05.115","article-title":"Diagnosis and management of pediatric papillary craniopharyngiomas","volume":"165","author":"Zhao","year":"2022","journal-title":"World Neurosurg"},{"key":"10.1016\/j.wneu.2025.124414_bib53","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1097\/CM9.0000000000002774","article-title":"Multi-omics analysis of adamantinomatous craniopharyngiomas reveals distinct molecular subgroups with prognostic and treatment response significance","volume":"137","author":"Wang","year":"2023","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.wneu.2025.124414_bib54","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1007\/s00401-014-1270-6","article-title":"BRAF V600E mutations are characteristic for papillary craniopharyngioma and may coexist with CTNNB1-mutated adamantinomatous craniopharyngioma","volume":"127","author":"Larkin","year":"2014","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.wneu.2025.124414_bib55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41572-019-0125-9","article-title":"Craniopharyngioma","volume":"5","author":"M\u00fcller","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.wneu.2025.124414_bib56","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1177\/1758834014566428","article-title":"Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma","volume":"7","author":"Welsh","year":"2015","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.wneu.2025.124414_bib57","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1001\/jamadermatol.2015.1745","article-title":"Cutaneous toxic effects of BRAF inhibitors alone and in combination with MEK inhibitors for metastatic melanoma","volume":"151","author":"Carlos","year":"2015","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.wneu.2025.124414_bib58","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0067583","article-title":"Dabrafenib; preclinical characterization, increased efficacy when combined with trametinib, while BRAF\/MEK tool combination reduced skin lesions","volume":"8","author":"King","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.wneu.2025.124414_bib59","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1016\/S0140-6736(12)60398-5","article-title":"Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial","volume":"379","author":"Falchook","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.wneu.2025.124414_bib60","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00401-011-0841-z","article-title":"Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody","volume":"122","author":"Capper","year":"2011","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.wneu.2025.124414_bib61","doi-asserted-by":"crossref","DOI":"10.3171\/2016.9.FOCUS16325","article-title":"Diagnosis and management of craniopharyngiomas in the era of genomics and targeted therapy","volume":"41","author":"Martinez-Gutierrez","year":"2016","journal-title":"FOC"},{"key":"10.1016\/j.wneu.2025.124414_bib62","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/neup.12408","article-title":"High-resolution melting and immunohistochemical analysis efficiently detects mutually exclusive genetic alterations of adamantinomatous and papillary craniopharyngiomas","volume":"38","author":"Yoshimoto","year":"2017","journal-title":"Neuropathology"},{"key":"10.1016\/j.wneu.2025.124414_bib63","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3171\/2017.4.JNS163113","article-title":"Prediction of BRAF mutation status of craniopharyngioma using magnetic resonance imaging features","volume":"129","author":"Yue","year":"2018","journal-title":"JNS"},{"key":"10.1016\/j.wneu.2025.124414_bib64","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1093\/neuros\/nyy569","article-title":"A clinical rule for preoperative prediction of BRAF mutation status in craniopharyngiomas","volume":"85","author":"Fujio","year":"2018","journal-title":"Neurosurg"},{"key":"10.1016\/j.wneu.2025.124414_bib65","doi-asserted-by":"crossref","DOI":"10.1016\/j.lpm.2021.104078","article-title":"Craniopharyngiomas","volume":"50","author":"Hamblin","year":"2021","journal-title":"Presse Med"},{"key":"10.1016\/j.wneu.2025.124414_bib66","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.cnc.2016.02.009","article-title":"The impact of liver and renal dysfunction on the pharmacokinetics and pharmacodynamics of sedative and analgesic drugs in critically ill adult patients","volume":"28","author":"Yogaratnam","year":"2016","journal-title":"Crit Care Nurs Clin North Am"},{"key":"10.1016\/j.wneu.2025.124414_bib67","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1007\/s11102-008-0165-8","article-title":"Craniopharyngioma: historical notes","volume":"12","author":"Lindholm","year":"2009","journal-title":"Pituitary"},{"key":"10.1016\/j.wneu.2025.124414_bib68","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s00381-018-3925-4","article-title":"Papillary craniopharyngioma in a 4-year-old girl with BRAF V600E mutation: a case report and review of the literature","volume":"35","author":"Borrill","year":"2018","journal-title":"Childs Nerv Syst"},{"key":"10.1016\/j.wneu.2025.124414_bib69","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1126\/science.aaa6204","article-title":"T cell exclusion, immune privilege, and the tumor microenvironment","volume":"348","author":"Joyce","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.wneu.2025.124414_bib70","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","article-title":"Understanding the tumor immune microenvironment (TIME) for effective therapy","volume":"24","author":"Binnewies","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.wneu.2025.124414_bib71","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s12943-021-01428-1","article-title":"Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives","volume":"20","author":"Mao","year":"2021","journal-title":"Mol Cancer"},{"key":"10.1016\/j.wneu.2025.124414_bib72","doi-asserted-by":"crossref","first-page":"26","DOI":"10.3390\/cells9010026","article-title":"The roles of CD38 and CD157 in the solid tumor microenvironment and cancer immunotherapy","volume":"9","author":"Wo","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.wneu.2025.124414_bib73","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.995655","article-title":"Immune infiltration in aggressive papillary craniopharyngioma: high infiltration but low action","volume":"13","author":"Jia","year":"2022","journal-title":"Front Immunol"}],"container-title":["World Neurosurgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878875025007703?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878875025007703?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T05:03:08Z","timestamp":1779771788000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878875025007703"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":73,"alternative-id":["S1878875025007703"],"URL":"https:\/\/doi.org\/10.1016\/j.wneu.2025.124414","relation":{},"ISSN":["1878-8750"],"issn-type":[{"value":"1878-8750","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeted Therapy for Recurrent and Refractory Papillary Craniopharyngioma: A Systematic Narrative Review","name":"articletitle","label":"Article Title"},{"value":"World Neurosurgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.wneu.2025.124414","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"124414"}}